StockData
Pasithea Therapeutics Corp. logo

Pasithea Therapeutics Corp. (KTTA) stock

KTTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.51+0.08 (+17.64%)

Close on Nov 18, 2026Market cap $17.07MP/E –Yield –

Pasithea Therapeutics cash

Cash and short-term investments held at the end of each period.

Pasithea Therapeutics's cash was $45.66M at Jun 30, 2026. For fiscal 2025 it was $55.16M, up 696.8% from the year before. The highest annual figure on record is $55.16M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$55.16M+696.8%
FY2024Dec 31, 2024$6.92M-57.6%
FY2023Dec 31, 2023$16.33M-50.6%
FY2022Dec 31, 2022$33.09M-37.5%
FY2021Dec 31, 2021$52.90M+21612.3%
FY2020Dec 31, 2020$243.65K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$45.66M+532.7%
Q1 FY2026Mar 31, 2026$50.40M+843.6%
Q4 FY2025Dec 31, 2025$55.16M+696.8%
Q3 FY2025Sep 30, 2025$4.12M-56.0%
Q2 FY2025Jun 30, 2025$7.22M-9.4%
Q1 FY2025Mar 31, 2025$5.34M-55.5%
Q4 FY2024Dec 31, 2024$6.92M-57.6%
Q3 FY2024Sep 30, 2024$9.36M-52.4%
Q2 FY2024Jun 30, 2024$7.97M-70.2%
Q1 FY2024Mar 31, 2024$12.01M-59.9%
Q4 FY2023Dec 31, 2023$16.33M-50.6%
Q3 FY2023Sep 30, 2023$19.68M-53.6%
Q2 FY2023Jun 30, 2023$26.77M-44.1%
Q1 FY2023Mar 31, 2023$29.91M-40.6%
Q4 FY2022Dec 31, 2022$33.09M-37.5%
Q3 FY2022Sep 30, 2022$42.38M+106.1%
Q2 FY2022Jun 30, 2022$47.90M+8317.9%
Q1 FY2022Mar 31, 2022$50.32M+4599.7%
Q4 FY2021Dec 31, 2021$52.90M+21612.3%
Q3 FY2021Sep 30, 2021$20.57M+227644.4%
Q2 FY2021Jun 30, 2021$568.98K–
Q1 FY2021Mar 31, 2021$1.07M–
Q4 FY2020Dec 31, 2020$243.65K–
Q3 FY2020Sep 30, 2020$9.03K–

More Pasithea Therapeutics figures

See a number that looks wrong?